AU2003258050A1 - 5-cycloalkenyl 5h-chromeno(3,4-f)quinoline derivatives as selective progesterone receptor modulator compounds - Google Patents
5-cycloalkenyl 5h-chromeno(3,4-f)quinoline derivatives as selective progesterone receptor modulator compoundsInfo
- Publication number
- AU2003258050A1 AU2003258050A1 AU2003258050A AU2003258050A AU2003258050A1 AU 2003258050 A1 AU2003258050 A1 AU 2003258050A1 AU 2003258050 A AU2003258050 A AU 2003258050A AU 2003258050 A AU2003258050 A AU 2003258050A AU 2003258050 A1 AU2003258050 A1 AU 2003258050A1
- Authority
- AU
- Australia
- Prior art keywords
- chromeno
- cycloalkenyl
- receptor modulator
- progesterone receptor
- quinoline derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000002379 progesterone receptor modulator Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41797502P | 2002-10-11 | 2002-10-11 | |
| US60/417,975 | 2002-10-11 | ||
| PCT/US2003/024419 WO2004033460A1 (en) | 2002-10-11 | 2003-08-04 | 5-cycloalkenyl 5h-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003258050A1 true AU2003258050A1 (en) | 2004-05-04 |
Family
ID=31994319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003258050A Abandoned AU2003258050A1 (en) | 2002-10-11 | 2003-08-04 | 5-cycloalkenyl 5h-chromeno(3,4-f)quinoline derivatives as selective progesterone receptor modulator compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7071205B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1551845A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006508076A (cg-RX-API-DMAC7.html) |
| AR (1) | AR040782A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003258050A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2500758A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2003001544A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1055058A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05003721A (cg-RX-API-DMAC7.html) |
| TW (1) | TW200410968A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004033460A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US7026484B2 (en) | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
| DE20301728U1 (de) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen |
| AU2003258047A1 (en) * | 2002-10-11 | 2004-05-04 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO-5H-CHROMENO(3,4-f)QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS |
| AR040782A1 (es) * | 2002-10-11 | 2005-04-20 | Ligand Pharm Inc | Derivados de 5- cicloalquenil-5h- cromeno [ 3,4- f] quinolina como compuestos mudulares selectivos de receptores de progesterona |
| BRPI0413820A (pt) * | 2003-08-22 | 2006-10-24 | Ligand Pharm Inc | derivados de 6-cicloamino-2-quinolinona como compostos moduladores de receptor de androgênio |
| EP1891067B1 (en) | 2005-06-17 | 2016-01-13 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| KR101505202B1 (ko) | 2006-03-07 | 2015-03-27 | 지타 쉬로프 | 인간 배아 줄기 세포 및 그의 유도체를 포함하는 조성물, 그의 사용 방법 및 제조 방법 |
| EP3947388A4 (en) | 2019-04-02 | 2022-12-21 | Aligos Therapeutics, Inc. | PRMT5 TARGETING COMPOUNDS |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5808139A (en) | 1992-04-21 | 1998-09-15 | Ligand Pharmaceuticals Incorporated | Non-steroid progesterone receptor agonist and antagonist and compounds and methods |
| US6696103B1 (en) * | 1993-03-19 | 2004-02-24 | Sumitomo Electric Industries, Ltd. | Aluminium nitride ceramics and method for preparing the same |
| US5506102A (en) | 1993-10-28 | 1996-04-09 | Ligand Pharmaceuticals Incorporated | Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription |
| DK0800519T3 (da) | 1994-12-22 | 2004-03-01 | Ligand Pharm Inc | Steroidreceptormodulatorforbindelser og fremgangsmåder |
| US6696459B1 (en) | 1994-12-22 | 2004-02-24 | Ligand Pharmaceuticals Inc. | Steroid receptor modulator compounds and methods |
| US5693647A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| US6380207B2 (en) * | 1998-02-13 | 2002-04-30 | Abbott Laboratories | Glucocortiocoid-selective antiinflammatory agents |
| ES2192035T3 (es) * | 1998-02-13 | 2003-09-16 | Abbott Lab | Agentes anti-inflamatorios que presentan una selectividad para los glucocorticoides. |
| US6506766B1 (en) * | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| US6001846A (en) * | 1998-02-17 | 1999-12-14 | Ligand Pharmaceuticals Incorporated | Process for the preparation of 1,2-dihydroquinolines |
| US6093825A (en) | 1998-05-27 | 2000-07-25 | American Home Products | Methods for preparation of 1,2-dihydroquinolines |
| US6093826A (en) | 1998-06-08 | 2000-07-25 | Ligand Pharmaceuticals Incorporated | Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines |
| AU761269B2 (en) * | 1999-01-16 | 2003-05-29 | Ciba Specialty Chemicals Water Treatments Limited | Production of acrylic monomers |
| US6319912B1 (en) | 1999-05-04 | 2001-11-20 | American Home Products Corporation | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides |
| US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
| US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
| US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| US6380178B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
| US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
| AU4501800A (en) | 1999-05-04 | 2000-11-17 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
| US6339098B1 (en) | 1999-05-04 | 2002-01-15 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
| AU4980100A (en) | 1999-05-04 | 2000-11-17 | American Home Products Corporation | Compositions containing benzimidazolones and progestogens |
| WO2000066560A1 (en) | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6423699B1 (en) | 1999-05-04 | 2002-07-23 | American Home Products Corporation | Combination therapies using benzimidazolones |
| US6306851B1 (en) | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
| US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
| HK1043736B (en) | 1999-05-04 | 2005-04-01 | Wyeth | Contraceptive compositions containing antiprogestinic and progestinic |
| US6358947B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
| WO2000066592A1 (en) | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
| US6417214B1 (en) | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
| US6369056B1 (en) | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
| US6444668B1 (en) | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
| US6329416B1 (en) | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
| US6399593B1 (en) | 1999-05-04 | 2002-06-04 | Wyeth | Cyclic regimens using cyclic urea and cyclic amide derivatives |
| US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6172241B1 (en) | 1999-10-15 | 2001-01-09 | Ligand Pharmaceuticals Incorporated | Process for the preparation of 1,2-dihydroquinolines |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| AR040782A1 (es) * | 2002-10-11 | 2005-04-20 | Ligand Pharm Inc | Derivados de 5- cicloalquenil-5h- cromeno [ 3,4- f] quinolina como compuestos mudulares selectivos de receptores de progesterona |
| DE20301728U1 (de) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen |
| AU2003258047A1 (en) | 2002-10-11 | 2004-05-04 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO-5H-CHROMENO(3,4-f)QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS |
-
2003
- 2003-08-04 AR AR20030102795A patent/AR040782A1/es not_active Application Discontinuation
- 2003-08-04 AU AU2003258050A patent/AU2003258050A1/en not_active Abandoned
- 2003-08-04 MX MXPA05003721A patent/MXPA05003721A/es unknown
- 2003-08-04 WO PCT/US2003/024419 patent/WO2004033460A1/en not_active Ceased
- 2003-08-04 CL CL200301544A patent/CL2003001544A1/es unknown
- 2003-08-04 EP EP03808051A patent/EP1551845A1/en not_active Withdrawn
- 2003-08-04 JP JP2004543232A patent/JP2006508076A/ja active Pending
- 2003-08-04 CA CA002500758A patent/CA2500758A1/en not_active Abandoned
- 2003-08-04 TW TW092121282A patent/TW200410968A/zh unknown
- 2003-08-04 HK HK03105597A patent/HK1055058A2/xx not_active IP Right Cessation
- 2003-10-10 US US10/684,229 patent/US7071205B2/en not_active Expired - Lifetime
-
2006
- 2006-04-25 US US11/411,676 patent/US20060194827A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060194827A1 (en) | 2006-08-31 |
| MXPA05003721A (es) | 2005-06-17 |
| US7071205B2 (en) | 2006-07-04 |
| HK1055058A2 (en) | 2003-12-05 |
| TW200410968A (en) | 2004-07-01 |
| US20040152718A1 (en) | 2004-08-05 |
| EP1551845A1 (en) | 2005-07-13 |
| AR040782A1 (es) | 2005-04-20 |
| WO2004033460A1 (en) | 2004-04-22 |
| JP2006508076A (ja) | 2006-03-09 |
| CL2003001544A1 (es) | 2005-01-07 |
| CA2500758A1 (en) | 2004-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002323098A1 (en) | Selective estrogen receptor modulators | |
| AU2003245773A1 (en) | Vanilloid receptor modulators | |
| AU2003277576A1 (en) | Receptor function controlling agent | |
| AU2001246671A1 (en) | Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands | |
| AU2003283651A1 (en) | Methods for providing technical support over networks | |
| AU2003235696A1 (en) | Substituted 4-aminopyridine derivatives used as pest control agents | |
| AU2003295822A1 (en) | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | |
| AU2003285042A1 (en) | Nuclear hormone receptor compounds, products and methods employing same | |
| AU2001231664A1 (en) | Indol-3-yl derivatives | |
| AU2003281694A1 (en) | 6,11-4-carbon bridged ketolides | |
| AU2002356533A1 (en) | Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis | |
| AU2003247706A1 (en) | 6, 11-4-carbon bridged erythromycin derivatives | |
| EP1144431A3 (de) | 16-hydroxyestratriene als selektiv wirksame estrogene | |
| AU2003301299A1 (en) | Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators | |
| AU2003258050A1 (en) | 5-cycloalkenyl 5h-chromeno(3,4-f)quinoline derivatives as selective progesterone receptor modulator compounds | |
| AU2003248356A1 (en) | Beta3-adrenergic receptor agonists | |
| AU2003258047A1 (en) | 5-(1',1'-CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO-5H-CHROMENO(3,4-f)QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | |
| AU2003258051A1 (en) | 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO(3,4-f)QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS | |
| AU2673201A (en) | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | |
| AU2003252467A1 (en) | Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives | |
| AU3611099A (en) | Oxindole derivatives used as neurokinin receptor antagonists | |
| AU2002306586A1 (en) | Methods for modulating g2a receptor activity | |
| AU2002953252A0 (en) | Compositions, Compounds and Methods for their Preparation | |
| AU2001293697A1 (en) | N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives | |
| AU2003270471A1 (en) | Link system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |